• 90 people with Huntington's disease (HD) chorea were studied for 12 weeks.
  • 45 people were randomly selected to take AUSTEDO (deutetrabenazine) and 45 people were randomly selected to take placebo (inactive tablets).
  • People’s involuntary movements were measured at the beginning and end of the study, with movements also being observed at intervals throughout the 12-week period.
Picture of 2 figures standing next to some text that reads 45 people randomly selected to take AUSTEDO and placebo.

First goal of the study1

To measure the effectiveness of AUSTEDO on HD chorea using the Total Maximal Chorea (TMC) score.

Areas of the body used to measure the effectiveness of AUSTEDO® on HD chorea with the TMC score

Second goal of the study1,2

To evaluate the effects of AUSTEDO on:

  • Overall HD symptoms, as reported by people in the study and their doctors.
  • Limitations on people’s ability to perform daily activities.
Areas of the body used to measure the effectiveness of AUSTEDO® on HD chorea with the TMC score

Understanding the TMC score

The TMC score is used to determine the effectiveness of HD chorea treatment. Seven parts of the body—including the face, mouth, arms, and legs—are scored from 0 to 4, with 0 indicating no chorea. A complete TMC score ranges from 0 to 28. The lower the score, the less chorea, or involuntary movements, exhibited by the person.1,3

Picture of a couple with white text
overlay that reads "your next steps".

your
next
steps

Models are not
actual patient

Receive
updates

Sign up to have information about AUSTEDO tablets and Huntington’s chorea emailed to you.

Register for updates

You are about to leave this site

You are about to leave AUSTEDO.com and enter a website operated by a third party. Teva is not responsible for and does not control the content contained on this third-party website linked to AUSTEDO.com.

Are you a healthcare professional?

The information on this site is intended for healthcare professionals in the United States. Are you a healthcare professional in the United States?

References: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ. Teva Neuroscience, Inc. 2. Data on file. Teva Neuroscience, Inc. 3. Huntington Study Group. Unified Huntington’s disease rating scale: reliability and consistency. Mov Disord. 1996;11(2):136-142. doi:10.1002/mds.870110204